* Atea Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 61 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 2.8% in the last three months.
* Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $3.50, below its last closing price of $3.83.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.49 -0.50 -0.47 Beat 5.4
Sep. 30 2023 -0.45 -0.48 -0.40 Beat 16.1
Jun. 30 2023 -0.45 -0.47 -0.34 Beat 27.7
Mar. 31 2023 -0.47 -0.48 -0.43 Beat 9.9
Dec. -0.44 -0.45 -0.41 Beat 8.9
31 2022
Sep. 30 2022 -0.41 -0.44 -0.10 Beat 77.4
Jun. 30 2022 -0.53 -0.52 -0.38 Beat 27.4
Mar. 31 2022 -0.56 -0.58 -0.51 Beat 12.4
This summary was machine generated May 3 at 11:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments